Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial

CHEN-HUA LIUHuang, Chung-FengChung-FengHuangCHUN-JEN LIUDai, Chia-YenChia-YenDaiLiang, Cheng-ChaoCheng-ChaoLiangHuang, Jee-FuJee-FuHuangHung, Peir-HaurPeir-HaurHungHUNG-BIN TSAIMENG-KUN TSAIChen, Shih-IShih-IChenJOU-WEI LINYang, Sheng-ShunSheng-ShunYangTUNG-HUNG SUHUNG-CHIH YANGPEI-JER CHENDING-SHINN CHENChuang, Wan-LongWan-LongChuangYu, Ming-LungMing-LungYuJIA-HORNG KAO2023-04-212023-04-212013-12-030003-4819https://scholars.lib.ntu.edu.tw/handle/123456789/630400Data are limited on the efficacy and safety of pegylated interferon plus ribavirin for patients with hepatitis C virus genotype 1 (HCV-1) receiving hemodialysis.en28B GENETIC POLYMORPHISMS; DIALYSIS PATIENTS; PLUS RIBAVIRIN; TREATMENT DURATION; KIDNEY-TRANSPLANTATION; ANTIVIRAL THERAPY; VIRAL KINETICS; HCV PATIENTS; INFECTION; ALPHA-2A[SDGs]SDG3Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trialjournal article10.7326/0003-4819-159-11-201312030-00005242971892-s2.0-84984584179WOS:000328731000002https://scholars.lib.ntu.edu.tw/handle/123456789/434614